Overview
Read-Gene is a company focused on the commercialization of methods for detecting, preventing, and treating various types of malignant tumors. They offer innovative DNA tests that help in the accurate prevention and quicker initiation of treatment for individuals with genetic predispositions to cancer. The company collaborates with medical professionals from the International Center for Hereditary Cancers at the Pomeranian Medical University in Szczecin.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 5.10
- High
- PLN 5.10
- Low
- PLN 4.80
- Volume
- 396
- Avg. vol.
- 269.8
- Market cap
- PLN 59.42M
- P/E ratio
- 25.20
- EPS
- PLN 0.20
- Shares outstanding
- 11.79M
- 52-week
- PLN 4.80 – 5.26
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLRADGN00014
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 1.13m | USD -116.96k | USD 113.45k |
| Q1 2026 | USD 1.05m | USD 203.94k | USD 199.08k |
| Q4 2025 | USD 1.29m | USD 193.12k | USD 108.74k |
| Q3 2025 | USD 851.83k | USD -62.28k | USD -59.52k |
Results for Q3 2026:Nov 10, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2010-09-30. Active
35 1240 3927 1111 0010 0756 5222
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
4 public aid cases recorded, with a total value of $40,999.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 9, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $24,952 | PGE Obrót S.A. | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $6,309 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,426 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The following persons are authorized to submit declarations of will on behalf of the company: in the case of a one-person management board – the President of the Management Board or each of the commercial proxies independently, and in the case of a multi-member management board – the President of the Management Board independently, or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Jan Antoni Lubiński (73)  | Posiadanie 30,48% udziałów w spółce będącej właścicielem 67,06% akcji zgłaszanej spółki akcyjnej; Shareholder of a joint-stock company, 5.27%; Shareholder of a joint-stock company, 1.89% |
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Innowacyjna Medycynasp. z o.o. | 1,350.62 USD | 100% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | |
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | |
| Centralne Laboratorium Ochrony RadiologicznejResearch institute | $2,330,566.32 | clor.waw.pl | |
| IntodnaS.A. | $2,286,118.76 | intodna.com | |
| Clinchoicesp. z o.o. | $2,048,208.30 | clinchoice.com | |
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | |
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | |
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl | |
| Zakład Genetyki Sądowejsp. z o.o. | $727,654.12 | dna-zgs.pl |
Change history
| Date | Event |
|---|---|
| 2020-09-03 | PKD change (Removed: 22.1, 22.2, 22.3, 24.1, 24.4, 51, 51.55.Z, 52.3, 52.31.Z, 52.63.B, 72.30.Z, 72.40.Z, 73.10, 74.13.Z, 74.30.Z, 74.40.Z, 80.4, 80.42.B, 85.1, 93.05.Z; Added: 21.20.Z, 47.29.Z, 47.73.Z, 47.91.Z, 62.01.Z, 72.11.Z, 72.19.Z, 74.90.Z, 86.22.Z, 86.90.E) |
| 2009-06-19 | Share capital change (615,000.00 PLN → 589,500.50 PLN) |
| 2009-01-16 | Share capital change (500,000.00 PLN → 615,000.00 PLN) |
| 2005-09-27 | Entered in the register |
FAQ
Last updated: 2026-08-20